JP2022537658A5 - - Google Patents

Info

Publication number
JP2022537658A5
JP2022537658A5 JP2021572305A JP2021572305A JP2022537658A5 JP 2022537658 A5 JP2022537658 A5 JP 2022537658A5 JP 2021572305 A JP2021572305 A JP 2021572305A JP 2021572305 A JP2021572305 A JP 2021572305A JP 2022537658 A5 JP2022537658 A5 JP 2022537658A5
Authority
JP
Japan
Prior art keywords
domain
sequence
seq
polypeptide
nmdar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021572305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537658A (ja
JP7702884B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/065606 external-priority patent/WO2020245343A1/en
Publication of JP2022537658A publication Critical patent/JP2022537658A/ja
Publication of JP2022537658A5 publication Critical patent/JP2022537658A5/ja
Application granted granted Critical
Publication of JP7702884B2 publication Critical patent/JP7702884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021572305A 2019-06-05 2020-06-05 神経学的自己免疫疾患における中枢神経系を標的とする自己抗体に結合するキメラ自己抗体受容体(caar) Active JP7702884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19178541.9 2019-06-05
EP19178541 2019-06-05
PCT/EP2020/065606 WO2020245343A1 (en) 2019-06-05 2020-06-05 Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease

Publications (3)

Publication Number Publication Date
JP2022537658A JP2022537658A (ja) 2022-08-29
JP2022537658A5 true JP2022537658A5 (enExample) 2023-06-09
JP7702884B2 JP7702884B2 (ja) 2025-07-04

Family

ID=66857629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572305A Active JP7702884B2 (ja) 2019-06-05 2020-06-05 神経学的自己免疫疾患における中枢神経系を標的とする自己抗体に結合するキメラ自己抗体受容体(caar)

Country Status (6)

Country Link
US (1) US12617835B2 (enExample)
EP (1) EP3980458A1 (enExample)
JP (1) JP7702884B2 (enExample)
CN (1) CN114008204B (enExample)
CA (1) CA3141509A1 (enExample)
WO (1) WO2020245343A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112457415A (zh) * 2020-12-14 2021-03-09 成都仕康美生物科技有限公司 靶向MOG的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
FR3120866B1 (fr) * 2021-03-19 2025-02-28 Univ Toulouse 3 Paul Sabatier Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
EP4455160A4 (en) * 2021-12-15 2025-12-10 Shanghai Synvida Biotechnology Co Ltd PRODUCT AND METHOD OF TREATMENT FOR THROMBOCYTOPENIA
CN114957446B (zh) * 2022-05-31 2023-09-15 陕西脉元生物科技有限公司 与nmdar脑炎患者中的自身抗体结合的nmdar突变体及其构建方法
WO2024151640A1 (en) * 2023-01-09 2024-07-18 Saliogen Therapeutics, Inc. Transposase generated chimeric antigen receptor t cells
CN118566499B (zh) * 2024-08-02 2024-10-08 成都海默云因医学检验实验室有限公司 一种GluN1和GluN2B亚基融合表达检测抗NMDAR抗体的CBA方法及检测试剂
CN119708229B (zh) * 2024-12-19 2025-12-09 陕西脉元生物科技有限公司 一种抗人lgi1蛋白的人鼠嵌合单克隆抗体及其产品和应用
CN120098151B (zh) * 2025-05-12 2025-07-25 成都海默云因医学检验实验室有限公司 一种检测抗gababr抗体脑炎的重组蛋白和检测试剂
CN120485285A (zh) * 2025-07-18 2025-08-15 天津医科大学总医院 一种质粒载体、嵌合mog抗体受体t细胞及其应用
CN120624489B (zh) * 2025-08-18 2025-12-02 天津医科大学总医院 一种嵌合aqp4抗体受体、caar-t细胞及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP0973928B1 (en) 1997-03-11 2010-05-05 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
AU775525B2 (en) * 1999-01-22 2004-08-05 Auckland Technology Enabling Corporation Limited Vaccine-mediated treatment of neurological disorders
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
BR0108545A (pt) 2000-02-24 2004-06-29 Xcyte Therapies Inc Estimulação e concentração simultâneas das células
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7634360B2 (en) * 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
CA2697742C (en) * 2006-08-15 2017-10-03 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment and diagnosis of autoimmune encephalitis or epilepsy
CA2692501C (en) 2007-07-04 2017-10-10 Max-Delbrueck-Centrum Fuer Molekulare Medizin Hyperactive variants of the transposase protein of the transposon system sleeping beauty
CN101874895B (zh) * 2009-02-17 2013-01-02 南京大学医学院附属鼓楼医院 Cart作为制备治疗阿尔茨海默病药物的应用
EP2646578A4 (en) * 2010-11-29 2014-04-30 Kenneth Blum METHODS OF EVALUATING RESULTS OF TREATMENT OF BEHAVIORS WITH DISSATISFACTION SYNDROME (RDS) USING EXPRESSION PROFILING
US8648198B2 (en) * 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
GB201409234D0 (en) 2014-05-23 2014-07-09 Isis Innovation Method
CN108350071A (zh) * 2015-08-17 2018-07-31 德国神经退行性疾病中心 结合到抗N-甲基-D-天冬氨酸(NMDA)受体抗体的结合区的抗体或抗体片段或非Ig支架
US12048718B2 (en) * 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
CN107857712B (zh) * 2016-09-22 2022-09-09 烟台益诺依生物医药科技有限公司 (r)-3-甲基-2-(3-氧代酰胺基)正丁酸酯
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
EP3346001A1 (en) 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
WO2019236593A1 (en) * 2018-06-05 2019-12-12 The Trustees Of The University Of Pennsylvania Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells

Similar Documents

Publication Publication Date Title
US12435118B2 (en) Chimeric antigen receptor and natural killer cells expressing same
JP2023059873A5 (enExample)
JP2022109953A5 (enExample)
EP3472205B1 (en) Chimeric antigen receptor
JP2025060882A5 (enExample)
JP2025065142A5 (enExample)
JP2023071729A5 (enExample)
JP2021512615A5 (enExample)
EP1973573B1 (en) Methods and compositions for expanding t regulatory cells
JP2020513829A5 (enExample)
JP2021522790A5 (enExample)
JP2020529841A5 (enExample)
JP2021536265A5 (enExample)
JP2020511136A5 (enExample)
RU2018140056A (ru) Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
JP2023534808A5 (enExample)
Fremont et al. Biophysical studies of T-cell receptors and their ligands
CN115960264A (zh) 转化生长因子-β应答多肽及其使用方法
JP2018523484A5 (enExample)
JP2015513920A5 (enExample)
JP2019521704A5 (enExample)
JP7227630B2 (ja) Y182t突然変異を有するt細胞-抗原カプラおよびその方法ならびに使用
JP2019513394A5 (enExample)
JP2022515331A5 (enExample)
JP2021526795A5 (enExample)